Jay T Flatley has bought stock on 4 days since May 2017
Director at Rivian Automotive, Inc., and 3 other companies
SEC CIK 0001189130 · Filings on SEC.gov ↗
Jay T Flatley's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Companies
Every filing
90 filings since Jan 2016, newest first
Rivian Automotive, Inc. / De
Director
Zymergen Inc.
COB, Acting CEO
Rivian Automotive, Inc. / De
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina, Inc.
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
Illumina Inc
Director
About Jay T Flatley
Jay T. Flatley is an accomplished technology executive serving as an Independent Class III Director on the Board of Directors of Rivian Automotive, Inc. (RIVN) since May 2021, where he contributes to Audit and Compensation committees, leveraging his expertise in finance, controls, and governance.( At age 73, he is recognized for his independence under Nasdaq rules and active participation in board activities.(
Flatley holds a B.A. in Economics from Claremont McKenna College and B.S. and M.S. in Industrial Engineering from Stanford University.( His career highlights include co-founding and leading Molecular Dynamics as President and CEO from 1994 to 1998, culminating in its sale to Amersham Pharmacia Biotech, and a transformative tenure at Illumina, Inc., where he served as CEO from 1999 to 2016, scaling revenue from $1.3 million in 2000 to $2.2 billion in 2015 (64% CAGR), pioneering next-generation sequencing via the 2006 Solexa acquisition, and earning accolades like MIT Technology Review's 'World’s Smartest Company' in 2014.( He later acted as CEO of Zymergen (2021-2022) and holds current roles such as Director at Denali Therapeutics and Trustee at The Salk Institute.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.